Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06374290 · ClinicalTrials.gov registry record · Phase 1
Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT06374290 is a Phase 1 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 2 participants.
The verdict
NCT06374290, a Phase 1 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.
Interventions
- DRUG Bupropion
- DRUG Naltrexone (Vivitrol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-07-16 |
| Est. Completion | 2024-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06374290
The ClinicalTrials.gov registry entry for NCT06374290 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupropion is the first listed.
NCT06374290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06374290 about?
NCT06374290 is a clinical study titled "Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia". The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related...
What is the current status of trial NCT06374290?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2024-07-16. Estimated completion is 2024-12-04.
What interventions are being tested in trial NCT06374290?
The interventions under investigation include: Bupropion (DRUG), Naltrexone (Vivitrol) (DRUG).
Who is sponsoring clinical trial NCT06374290?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.